TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3933134
Drug: 10% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% mannitol mechanical bowel preparation combined with oral neomycin and short-term, perioperative intravenous Flagyl (group I)
Study: 31064779
Drug: low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose cytarabine (LDAC) alone
Study: 29050507
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment (Control Group)
Study: 16980507
Drug: LNG +
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LNG + Meloxicam (Melox) 15 mg
Study: 7007840
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with cimetidine (400 mg twice a day)
Study: 7007840
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy with cimetidine (six-week courses for each relapse)
Study: 27893326
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and pemetrexed (platinum therapy)
Study: 27893326
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and pemetrexed (nonplatinum therapy)
Study: 25778467
Drug: GIK infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIK infusion for 12 hours
Study: 16249701
Drug: Lopinavir/ritonavir +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir + 2 nucleosides (triple therapy)
Study: 12072676
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of positive ions for 4 hrs followed by inhalation of air from a home humidifier generating O(2)(‐)(H(2)O)(n) for 4 hrs
Study: 30208421
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy (delivered via a light-emitting mask, peak 505 nm, 23 scotopic Td), worn each night for 12 months
Study: 24178368
Drug: Vemurafenib 480
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 480 mg bid
Study: 24178368
Drug: Vemurafenib 720
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 720 mg bid
Study: 24178368
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg bid
Study: 21760473
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg once daily
Study: 15868131
Drug: Subjective roughness
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective roughness scaling by 19 speech and voice therapy students
Study: 27836677
Drug: NEMEX therapy
Normalized name: Nemex
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEMEX therapy (neuro-muscular exercise) twice a week for 8 weeks
Study: 27836677
Drug: NEMEX therapy
Normalized name: Nemex
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEMEX therapy and PHARMA
Study: 23415779
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative treatment regimen without topical cyclosporine A
Study: 19154960
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamin E, 800 IU; vitamin C, 500 mg; beta-carotene, 10 mg)
Study: 16776335
Drug: Gamma knife
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma knife surgery to the retrogasserian cisternal portion of the fifth cranial nerve, median dose 85 Gy (range 70‐90 Gy)
Study: 11316215
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg p.o. b.i.d. for 3 months
Study: 7895895
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg low-molecular-weight dermatan sulphate
Study: 7895895
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg low-molecular-weight dermatan sulphate
Study: 7895895
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg and 200 mg low-molecular-weight dermatan sulphate
Study: 23765237
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy after invasive mechanical ventilation (RRT after IMV)
Study: 14731181
Drug: Vertical Guided
Normalized name: Verticalm
DrugBank: Meclizine (DB00737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertical Guided Bone Regeneration (GBR) with autogenous bone and e-PTFE membranes; 25 implants placed.
Study: 14731181
Drug: Distraction Osteogenesis
Normalized name: Osteogenic protein 1
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Distraction Osteogenesis (DO); 34 implants placed.
Study: 18655559
Drug: Cuichan Zhusheng
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuichan Zhusheng Decoction (CZD), 300 mL daily, taken orally for 3 days
Study: 18655559
Drug: Pitocin, 1
Normalized name: Pitocin, 10 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitocin, 1 U into 500 mL 5% glucose for intravenous dripping for 3 days
Study: 2894181
Drug: Temazepam 10
Normalized name: temazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 10 mg
Study: 21545399
Drug: naproxcinod 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxcinod 750 mg twice daily
Study: 9626829
Drug: Eptifibatide therapy
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide therapy
Study: 1460170
Drug: Global self‐ratings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Global self‐ratings administered twice a day
Study: 1460170
Drug: Itemized, prospective,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itemized, prospective, observer‐rated scale administered twice a day
Study: 27541314
Drug: Smartphone-delivered maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-delivered maintenance intervention based on acceptance and commitment therapy (ACT)
Study: 20204974
Drug: CAD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAD plus an additional four-session self-management group training (CAD+G, n = 31)
Study: 16225490
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 40 mg
Study: 16225490
Drug: Oral esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral esomeprazole 40 mg
Study: 16225490
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 20 mg
Study: 16225490
Drug: Oral esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral esomeprazole 20 mg
Study: 15674097
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole (both dosages)
Study: 8576661
Drug: Furosemide 1
Normalized name: furosemide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 1 mg/kg immediate preoperation
Study: 1970960
Drug: Plain tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tablets (500 mg theophylline)
Study: 394795
Drug: Baclofen 5
Normalized name: baclofen 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 5 mg qds
Study: 21458191
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin daily for 5 years
Study: 19353539
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g fenugreek fiber
Study: 19353539
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g fenugreek fiber
Study: 19353539
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g fenugreek fiber (control)
Study: 17509194
Drug: Letrozole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 7.5 mg
Study: 14980901
Drug: Desmopressin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.3 micro g/kg
Study: 8516091
Drug: Calf lung
Normalized name: Calf lung surfactant extract (CLSE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf lung surfactant extract (CLSE) administered at birth
Study: 8516091
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (control group)
Study: 3436153
Drug: Hydrochlorothiazide/triamterene (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide/triamterene (25 mg/50 mg)
Study: 26537944
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g pure whey protein isolate (L)
Study: 16563324
Drug: TIVA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA group (propofol 2.0 mg/kg intravenously by bolus injection and fentanyl 2 microg/kg for induction; propofol 5 mg/kg per hour for maintenance)
Study: 19302581
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 7.5 mg/month
Study: 19302581
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 22.5 mg every 3 months
Study: 19302581
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (7.5 mg, 11.25 mg, 22.5 mg)
Study: 2645824
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (metoprolol and propranolol)
Study: 788760
Drug: Brolitene (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolitene (1200 mg per day, 6 tablets)
Study: 30566641
Drug: Water supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water supplementation (1.5 L daily for 6 weeks)
Study: 28660719
Drug: Participants not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants not using insulin in the intervention group
Study: 28660719
Drug: Participants not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants not using insulin in the control group
Study: 20186397
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered oxytocin
Study: 15126990
Drug: Laronidase (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laronidase (100 U/kg, 0.58 mg/kg) administered intravenously weekly for 26 weeks
Study: 15126990
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously weekly for 26 weeks
Study: 9143566
Drug: Intravenous gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gentamicin and chloramphenicol
Study: 3240302
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk supplemented with 1 mmol NaH2PO4 per 100 ml
Study: 28389125
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antiplatelet, statin and blood pressure lowering drugs
Study: 28389125
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of BP-lowering drugs and statins at discharge
Study: 18667842
Drug: Topical methimazole
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methimazole 5%
Study: 18667842
Drug: Oral methimazole
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methimazole 5 mg tablet
Study: 19363280
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg daily for 20 days
Study: 14766711
Drug: Urapidil 10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 10-15 mg h(-1) continuous i.v. infusion for 3 days before surgery and until adrenal gland removal
Study: 26142266
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy optimization
Study: 20214337
Drug: CPSG 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPSG 5 g per day for 2 weeks
Study: 15105217
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg and Placebo
Study: 11298484
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (Aldara)
Study: 23963030
Drug: Intra-arterial octreotide
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial octreotide (5 mL 500µg)
Study: 23963030
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 mL 0.9% saline solution)
Study: 3816920
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (500 mg)
Study: 3816920
Drug: Captopril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (40 +/- 13 mg)
Study: 30329160
Drug: 3-dimensional conformal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dimensional conformal radiation therapy (3DCRT)
Study: 18800957
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg PO BID
Study: 15785917
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance with mandible advance (12 patients)
Study: 15785917
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance without mandible advance (12 patients)
Study: 12719065
Drug: Self-administered health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered health status questionnaire
Study: 10875161
Drug: Rufloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin (200 mg single oral dose three hours before surgery)
Study: 25727335
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (NaCl 0.9%)
Study: 12534583
Drug: Aspirin 500
Normalized name: aspirin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 500 mg
Study: 1391958
Drug: OKY-046 400
Normalized name: OKI-179
DrugBank: OKI-179 (DB17583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY-046 400 mg
Study: 30921401
Drug: Antibiotic impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic impregnated CVCs
Study: 30921401
Drug: Heparin bonded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bonded CVCs
Study: 22026446
Drug: Warfarin re-administration
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin re-administration 3 days after burr hole drainage to reach target INR range of 1.7-2.5
Study: 22026446
Drug: Warfarin re-administration
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin re-administration 3 days after burr hole drainage
Study: 16160759
Drug: Project ALERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Project ALERT drug prevention program
Study: 11711839
Drug: Latanoprost ophthalmic
Normalized name: latanoprost ophthalmic
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost ophthalmic solution
Study: 7900456
Drug: combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined chemotherapy with tranquilizers, antidepressants, neuroleptics
Study: 2452920
Drug: Indoramin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (50 mg daily for 8 days)
Study: 2452920
Drug: Indoramin (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (chronic administration)
Study: 20811347
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (ACEIs)
Study: 2441167
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 mg terazosin
Study: 2441167
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 mg prazosin
Study: 18204417
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) co-administered with other bipolar medications
Study: 8976948
Drug: iodixanol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol (320 mg I/ml)
Study: 8976948
Drug: iodixanol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol (300 mg I/ml)
Study: 31185379
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rheumatoid factor, matrix metalloproteinase‐9 and total homocysteine
Study: 26621634
Drug: 20-µg vitamin
Normalized name: vitamin E 20 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-µg vitamin D3 daily for 12 weeks
Study: 23768267
Drug: HPV 16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV 16/18 vaccine
Study: 22492244
Drug: HAV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccine
Study: 11035136
Drug: 4162W94 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4162W94 300 mg i.v. for 5 consecutive days
Study: 8622092
Drug: Sustained-release hydromorphone
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release hydromorphone (SRH)
Study: 8622092
Drug: Immediate-release hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release hydromorphone (IRH)
Study: 31600343
Drug: ART at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART at any CD4 cell count with enhanced support for ART and substance use treatment
Study: 27484880
Drug: Tamoxifen (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (both doses)
Study: 21750485
Drug: rFVIIa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (100 mcg/Kg b.w.)
Study: 10456450
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate (600 mg intramuscularly on the second day before surgery, then 300 mg once daily)
Study: 6284564
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g die i.v. for 7 days
Study: 6284564
Drug: Gentamicin 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 240 mg die i.m. for 7 days
Study: 31663156
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication review with patient involvement (questionnaire and telephone call with pharmacist)
Study: 27453302
Drug: Systemic targeted-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic targeted- and immunotherapy (e.g., ipilimumab, pembrolizumab, nivolumab, vemurafenib, dabrafenib plus trametinib)
Study: 19897678
Drug: T(4) therapy
Normalized name: 4-T-BUTYLCYCLOHEXANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: T(4) therapy
Study: 10403324
Drug: Six-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-dose regimen of artemether-lumefantrine (480 mg artemether and 2880 mg lumefantrine)
Study: 10403324
Drug: Four-dose regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose regimen of artemether-lumefantrine (320 mg artemether and 1920 mg lumefantrine)
Study: 21107435
Drug: OM/HCTZ 40/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM/HCTZ 40/12.5 mg
Study: 21107435
Drug: OM/HCTZ 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM/HCTZ 20/12.5 mg
Study: 21107435
Drug: OM 40
Normalized name: Aptiom 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM 40 mg
Study: 9542676
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate emollient 0.05% twice daily (n = 41)
Study: 9542676
Drug: Emollient vehicle
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient vehicle twice daily (n = 40)
Study: 8001065
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (1% applied 4 times a year, 0.7 ml applied interdentally)
Study: 8001065
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (applied 4 times a year, 0.7 ml applied interdentally)
Study: 2086824
Drug: CEMT-PI-L (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEMT-PI-L (250 mg, 2 times a day)
Study: 2086824
Drug: CCL (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCL (500 mg, 3 times a day)
Study: 2086824
Drug: CEMT-PI-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEMT-PI-L
Study: 25468954
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) treatment with titration regimen, reduced to 2.5 mg daily after about 5 months, discontinued after 5 months (Group 1)
Study: 25468954
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) treatment with titration regimen, reduced to 2.5 mg every other day after 5 months, discontinued after a further 5 months (Group 2)
Study: 25468954
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with antithyroid drugs (ATD)
Study: 23671210
Drug: Artiste Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artiste Assisted Injection System
Study: 7843592
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of l-moprolol and dipivefrin
Study: 3049116
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor (TF) administered to 22 patients with Hodgkin's disease.